Results 1 to 10 of about 5,732 (211)

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

Frontiers in Immunology, 2023
Bispecific antibodies have attracted more attention in recent years for the treatment of tumors, in which most of them target CD3, which mediates the killing of tumor cells by T cells.
Xinghui Xiao, Xinghui Xiao, Ying Cheng, Ying Cheng, Xiaodong Zheng, Xiaodong Zheng, Yuhang Fang, Yuhang Fang, Yu Zhang, Yu Zhang, Rui Sun, Rui Sun, Zhigang Tian, Zhigang Tian, Zhigang Tian, Haoyu Sun, Haoyu Sun   +16 more
doaj   +3 more sources

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

OncoImmunology, 2021
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse.
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Céline Amara, Cédric Barrière, Justine Siavellis, Valérie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Véronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel, Angéla Virone-Oddos   +25 more
doaj   +2 more sources

Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice [PDF]

Nature Communications
Tumor infiltrating T cells (TIL) are key players in the anti-tumor immune response. However, chronic exposure to tumor-derived antigens drives the differentiation into ‘exhausted’ TILs.
Xuhao Zhang, Yu Gao, Wenbo Hu, Yong Liang, Xiaozhe Yin, Xiangjun Shi, Hongjia Li, Huiping Liao, Jingya Guo, Xiaohong Yu, Mingzhao Zhu, Hua Peng, Wenyan Wang, Yang-Xin Fu   +13 more
doaj   +2 more sources

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy [PDF]

Signal Transduction and Targeted Therapy
T cell engager (TCE) immunotherapies have revolutionized the landscape of cancer treatment; however, their efficacy remains limited by the inaccessibility of intracellular tumor antigens.
Ziqiang Ding, Shuyang Sun, Xiaomei Yang, Xianing Huang, Xiaoqiong Hou, Shenxia Xie, Aiqun Liu, Xiaoling Lu   +7 more
doaj   +2 more sources

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

Biomedicines, 2020
Oncolytic viruses (OVs) are potent anti-cancer biologics with a bright future, having substantial evidence of efficacy in patients with cancer. Bi- and tri-specific antibodies targeting tumor antigens and capable of activating T cell receptor signaling ...
Zong Sheng Guo, Michael T. Lotze, Zhi Zhu, Walter J. Storkus, Xiao-Tong Song   +4 more
doaj   +3 more sources

Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy [PDF]

Journal for ImmunoTherapy of Cancer
Background Bispecific T cell engagers have demonstrated promising clinical progress in both hematologic malignancies and solid tumors; however, their therapeutic efficacy is still limited by multiple challenges including T cell anergy resulting from ...
Qi Sun, Ying Wang, Qin Liu, Baorui Liu, Jie Shao, Fangcen Liu, Xiaotong Chen, Jingyi Guo, Mengzhu Li, Tianran Chen, Yuxiang Li, Jiayao Yan, Jiaqi Nie   +12 more
doaj   +2 more sources

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma

PLoS ONE, 2022
Cholangiocarcinoma (CCA) is a lethal cancer of bile duct epithelial cells with a high mortality rate and limited therapeutic options. An effective treatment is, therefore, urgently needed to improve treatment outcomes for these patients. To develop a new
Thanich Sangsuwannukul, Kamonlapat Supimon, Thaweesak Chieochansin, Kornkan Choomee, Jatuporn Sujjitjoon, Mutita Junking, Pa-thai Yenchitsomanus   +6 more
doaj   +2 more sources

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Journal of Hematology & Oncology, 2023
Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu   +12 more
doaj   +1 more source

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy

Clinical Case Reports, 2020
The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.
Francesco Paolo Tambaro, Sajad Khazal, Cesar Nunez, Dristhi Ragoonanan, Priti Tewari, Demetrios Petropoulos, Partow Kebriaei, William George Wierda, Kris Michael Mahadeo   +8 more
doaj   +1 more source

Bi-, tri-, and multi-specific T-cell engager therapies in glioblastoma: a decade of preclinical innovation [PDF]

Exploration of Neuroscience
Background: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, with a poor prognosis despite advances in treatment options. T-cell-engager therapies, which have an antibody-based structure connecting immune cells to
Adam H. Lapidus, Malaka Ameratunga
doaj   +1 more source